Ketamine and Esketamine for Suicidal Ideation: New Meta-Analysis Highlights Evidence Gaps

Meta-Analysis Finds Ketamine Reduces Suicidal Ideation Acutely in Depression

A systematic review and meta-analysis published on November 11, 2026, synthesizes evidence from 12 randomized controlled trials (RCTs) to assess the effects of ketamine and esketamine on suicidal ideation in adults with depression (OpenAlex W7225789115). The review found that intravenous ketamine is associated with a moderate reduction in suicidal-ideation severity within 24 hours post-treatment (Hedges' g = −0.76, 95% CI −1.14 to −0.38; I² = 6%), based on five RCTs with 247 participants. In contrast, esketamine, the S-enantiomer and FDA-approved intranasal formulation, showed a smaller and statistically uncertain effect (g = −0.21, 95% CI −0.44 to 0.02; two trials, 286 participants). The evidence for both agents’ ability to induce remission of suicidal ideation or prevent suicide attempts remains imprecise due to limited and heterogeneous data.

Mechanism, Clinical Context, and Study Limitations

Ketamine’s rapid-acting antidepressant and anti-suicidal effects are thought to involve N-methyl-D-aspartate (NMDA) receptor antagonism, leading to downstream glutamate signaling and synaptic plasticity changes. This mechanism is distinct from conventional antidepressants, which often require weeks to achieve clinical benefit. The meta-analysis highlights that while ketamine may acutely reduce suicidal ideation, the durability of this effect is unclear, and the magnitude of benefit may be overestimated in small, unblinded studies. Esketamine’s weaker evidence base may reflect differences in dosing, administration route, or trial design, as well as the challenge of separating drug effects from placebo in populations with high baseline risk and fluctuating symptoms.

Notably, the review underscores that most included trials were small, often single-site, and methodologically limited—frequently lacking robust masking or standardized outcome measures for suicidality. This raises concerns about bias and generalizability, especially as regulatory and clinical decisions increasingly reference these data.

Policy, Regulatory, and Research Implications

The meta-analysis provides moderate-certainty evidence supporting ketamine’s short-term benefit for suicidal ideation in depression, but it also exposes critical gaps that complicate policy and regulatory decisions. The U.S. Food and Drug Administration (FDA) has approved intranasal esketamine (Spravato) for treatment-resistant depression and, under a Risk Evaluation and Mitigation Strategy (REMS), for depressive symptoms in adults with acute suicidal ideation or behavior. However, the present review suggests that the evidence for esketamine’s efficacy in reducing suicidal ideation specifically is limited and imprecise, which may prompt regulators to re-examine the strength of current indications or post-marketing surveillance requirements.

For clinicians, these findings reinforce the need for caution when considering ketamine or esketamine for patients with acute suicidality, especially outside of controlled research settings. The authors call for larger, better-masked RCTs with standardized suicidality measures and longer follow-up periods to clarify both efficacy and safety. An underappreciated challenge is the potential for functional unblinding in ketamine trials—participants and clinicians may recognize psychoactive effects, inadvertently biasing outcomes. Future trials may need to incorporate active placebos or novel masking strategies to address this limitation, a nuance often overlooked in regulatory and industry discussions.

Risks, Safety Signals, and Remaining Unknowns

Both ketamine and esketamine were associated with increased rates of dissociation, dizziness, and elevated blood pressure compared to placebo, although the safety data are sparse and inconsistently reported. The risk of misuse, dependency, and long-term neurocognitive effects remains insufficiently characterized in the depression and suicidality context. Importantly, the review found no clear evidence that either drug reduces suicide attempts or self-harm events, highlighting a critical distinction between reducing ideation and preventing behavior.

Acceptability, defined as treatment discontinuation for any reason, was not systematically different between groups, but the limited sample sizes and short follow-up periods restrict interpretation. The lack of data on long-term outcomes, repeated dosing, and real-world patient populations further limits the ability to draw firm conclusions for clinical practice or health policy.

Looking Forward: Priorities for Research and Practice

Future research must address the durability of ketamine’s anti-suicidal effects, optimal dosing regimens, and comparative effectiveness versus standard care or other rapid-acting interventions. Policymakers and funding agencies should prioritize large, multisite RCTs with rigorous masking, standardized suicidality assessments, and at least six-month follow-up to inform guidelines and regulatory decisions. For now, the acute reduction in suicidal ideation with ketamine remains a cautiously promising but incomplete answer to an urgent clinical need, and the field must guard against premature adoption in the absence of robust, long-term safety and efficacy data.

Reviewed by Dr. Alex Rivera, MD, MSc (Clinical Psychiatry), on 2026-11-13. Research based on primary source meta-analysis and FDA regulatory documentation.